22 Jun
2021

Arthrex will make IPRs more expensive and uncertain, and the USPTO Director more powerful

The long-term implications of the Supreme Court’s Arthrex decision are so profound that Congress should take a new look at the entire IPR process. The chances are it won’t, though

Joff Wild

Author | Editor-in-chief

[email protected]

Joff Wild